The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521 (Updated)

被引：0

作者：

Hall, W. A. ^{[1
]}

Karrison, T. G. ^{[2
]}

Rosenthal, S. A. ^{[3
]}

Amin, M. ^{[4
]}

Gomella, L. G. ^{[5
]}

Purdy, J. A. ^{[6
]}

Sartor, O. ^{[7
]}

Michalski, J. M. ^{[8
]}

Garzotto, M. ^{[9
]}

Bergom, C. ^{[1
]}

Jani, A. ^{[10
]}

Lawton, C. A. F. ^{[11
]}

Simko, J. ^{[12
]}

Moore, J. ^{[13
]}

Gore, E. M. ^{[11
]}

Lee, W. R. ^{[14
]}

Nguyen, P. L. ^{[15
]}

Danielson, B. L. ^{[16
]}

Sandler, H. M. ^{[17
]}

Feng, F. Y. ^{[18
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] NRG Oncol SDMC, Philadelphia, PA USA

[3] Sutter Med Grp & Canc Ctr, Sacramento, CA USA

[4] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA

[5] Thomas Jefferson Univ, Dept Urol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[6] UC Davis Canc Ctr, Davis, CA USA

[7] Tulane Univ, New Orleans, LA 70118 USA

[8] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA

[9] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[10] Emory Univ, Dept Radiat Oncol, Winship Canc Inst, Atlanta, GA 30322 USA

[11] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA

[12] Univ Calif San Francisco, San Francisco, CA 94143 USA

[13] Wellspan Hlth, York, PA USA

[14] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA

[15] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA

[16] Cross Canc Inst, Div Radiat Oncol, Edmonton, AB, Canada

[17] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[18] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 108卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3294

引用

页码：E562 / E563

页数：2

共 9 条

[1] The Influence of the Pretreatment Host Immune Inflammatory State and Response to Radiation Therapy in High-Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521
Hall, W. A.
Karrison, T. G.
Rosenthal, S. A.
Amin, M.
Gomella, L. G.
Purdy, J. A.
Sartor, O.
Michalski, J. M.
Garzotto, M.
Bergom, C.
Jani, A.
Lawton, C. A. F.
Simko, J.
Moore, J.
Gore, E. M.
Lee, W. R.
Nguyen, P. L.
Danielson, B.
Sandler, H. M.
Feng, F. Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S13 - S14
[2] The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521
Hall, William A.
Karrison, Theodore G.
Rosenthal, Seth A.
Amin, Mahul B.
Gomella, Leonard G.
Purdy, James A.
Sartor, A. Oliver
Michalski, Jeff M.
Garzotto, Mark G.
Bergom, Carmen
Jani, Ashesh B.
Lawton, Colleen A. F.
Simko, Jeffry P.
Moore, Joan K.
Gore, Elizabeth M.
Lee, W. Robert
Nguyen, Paul L.
Danielson, Brita L.
Sandler, Howard M.
Feng, Felix Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (02): : 266 - 274
[3] Validation of a Genomic Classifier in the NRG Oncology/ RTOG 0521 Phase Ill Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer
Phillips, R.
Proudfoot, J.
Davicioni, E.
Spratt, D. E.
Feng, F. Y.
Simko, J.
Den, R. B.
Pollack, A.
Rosenthal, S. A.
Sartor, O.
Sweeney, C.
Attard, G.
Patel, S. I.
Hall, W. A.
Efstathiou, J. A.
Shah, A. B.
Hoffman, K. E.
Pugh, S.
Sandler, H. M.
Tran, P. T.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S34 - S35
[4] Adjuvant Radiation Therapy, Androgen Deprivation, and Docetaxel for High-Risk Prostate Cancer Postprostatectomy: Results of NRG Oncology/RTOG Study 0621
Hurwitz, Mark D.
Harris, Jonathan
Sartor, Oliver
Xiao, Ying
Shayegan, Bobby
Sperduto, Paul W.
Badiozamani, Kasra R.
Lawton, Colleen A. F.
Horwitz, Eric M.
Michalski, Jeff M.
Roof, Kevin
Beyer, David C.
Zhang, Qiang
Sandler, Howard M.
CANCER, 2017, 123 (13) : 2489 - 2496
[5] Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
Sartor, Oliver
Karrison, Theodore G.
Sandler, Howard M.
Gomella, Leonard G.
Amin, Mahul B.
Purdy, James
Michalski, Jeff M.
Garzotto, Mark G.
Pervez, Nadeem
Balogh, Alexander G.
Rodrigues, George B.
Souhami, Luis
Reaume, M. Neil
Williams, Scott G.
Hannan, Raquibul
Jones, Christopher U.
Horwitz, Eric M.
Rodgers, Joseph P.
Feng, Felix Y.
Rosenthal, Seth A.
EUROPEAN UROLOGY, 2023, 84 (02) : 156 - 163
[6] Experience-Based Quality Control in Radiation Therapy Treatment Planning of High Risk Post-prostatectomy Prostate Cancer with RapidPlan: NRG Oncology RTOG 0621
O'Grady, F.
Geng, H.
Zhong, H.
Huang, M.
Giaddui, T. G.
Hurwitz, M. D.
Xiao, Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E257 - E258
[7] A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).
Mihalcik, Stephen Andrew
Regan, Meredith M.
Rosenthal, Seth A.
Bubley, Glenn J.
Pienta, Kenneth J.
Gomella, Leonard G.
Grignon, David A.
Hartford, Alan C.
Morginstin, Mark S.
Michalski, Jeff M.
Rajan, Raghu
McDonald, Andrew Michael
Dominello, Michael M.
Atkins, James Norman
Jones, Christopher U.
Moughan, Jennifer
Sandler, Howard M.
Kaplan, Irving D.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902
Rosenthal, Seth A.
Hunt, Daniel
Sartor, Oliver
Pienta, Kenneth J.
Gomella, Leonard
Grignon, David
Rajan, Raghu
Kerlin, Kevin J.
Jones, Christopher U.
Dobelbower, Michael
Shipley, William U.
Zeitzer, Kenneth
Hamstra, Daniel A.
Donavanik, Viroon
Rotman, Marvin
Hartford, Alan C.
Michalski, Jeffrey
Seider, Michael
Kim, Harold
Kuban, Deborah A.
Moughan, Jennifer
Sandler, Howard
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (02): : 294 - 302
[9] Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) vs. Dose Escalated Radiation Therapy and Enhanced ADT with TAK-700 for Men with High-Risk Prostate Cancer (NRG Oncology/RTOG 1115)
Michaelson, D.
Dignam, J. J.
Hamstra, D. A.
Bachand, F.
Master, V.
Bruner, D. W.
Torres, M.
Saylor, P. J.
Wallace, R. E.
Vapiwala, N.
Efstathiou, J. A.
Roach, M., III
Rosenthal, S. A.
Raben, A.
Morgan, S. C.
Kavadi, V. S.
Spratt, D. E.
Michalski, J. M.
Rodgers, J.
Sandler, H. M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S67 - S68

← 1 →